Genetic variant associated with aggressive not indolent prostate cancer.


获取原文并翻译 | 示例


Genome wide association studies have identified over two dozen single nucleotide polymorphisms (SNPs) that are associated with an increased risk of developing prostate cancer. Of note, all of these designs were case-control studies. In order to better differentiate between aggressive and indolent prostate cancer, Xu et al. performed the first case-case study design where 4,829 patients with aggressive prostate cancer were compared to 12,205 patients with less aggressive disease as defined by Gleason score. Their work, published in a recent issue of Proceedings of the National Academy of Sciences, identified a genetic variant, rs4054823, which significantly distinguished between the two natures of prostate tumors. Results indicated a 25% increased likelihood of developing aggressive prostate cancer with the TT genotype (p = 2.1 x 10-6). While one biomarker alone does not warrant clinical change, this finding encourages future research to utilize a case-case genotyping methodology in order to effectively characterize risk of aggressive prostate cancer. Delineation would benefit clinicians in their diagnosis and treatment and ultimately would reduce the number of men who are over-treated from PSA-based screening.
机译:全基因组关联研究已经确定了超过二十两种单核苷酸多态性(SNP),它们与罹患前列腺癌的风险增加相关。值得注意的是,所有这些设计都是病例对照研究。为了更好地区分侵袭性和惰性前列腺癌,Xu等。进行了第一个案例研究设计,将4829例侵略性前列腺癌患者与12205例侵略性疾病较弱的患者(按照格里森评分定义)进行比较。他们的工作发表在最近出版的《美国国家科学院院刊》上,确定了一种遗传变异体rs4054823,该变异体显着区分了前列腺肿瘤的两种性质。结果表明,TT基因型发展为侵略性前列腺癌的可能性增加了25%(p = 2.1 x 10-6)。尽管仅一种生物标志物不能保证临床改变,但这一发现鼓励未来的研究利用病例-病例基因分型方法来有效地表征侵袭性前列腺癌的风险。划定将有益于临床医生的诊断和治疗,并最终减少因基于PSA的筛查而被过度治疗的男性人数。



  • 外文文献
  • 中文文献
  • 专利


京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号